190 related articles for article (PubMed ID: 32878553)
1. Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient.
Krämer I; Rosentreter J; Fried M; Kühn M
J Oncol Pharm Pract; 2021 Jun; 27(4):1000-1004. PubMed ID: 32878553
[TBL] [Abstract][Full Text] [Related]
2. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
3. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate-doxycycline interaction.
Tortajada-Ituren JJ; Ordovás-Baines JP; Llopis-Salvia P; Jiménez-Torres NV
Ann Pharmacother; 1999; 33(7-8):804-8. PubMed ID: 10466909
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
7. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
8. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
Breithaupt H; Küenzlen E
Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of methotrexate intoxication in a child with osteosarcoma.
Peyriere H; Cociglio M; Margueritte G; Vallat C; Blayac JP; Hillaire-Buys D
Ann Pharmacother; 2004 Mar; 38(3):422-7. PubMed ID: 14970366
[TBL] [Abstract][Full Text] [Related]
12. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
13. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
14. [High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis].
Brain E; Alexandre J; Minozzi C; Misset JL
Presse Med; 1997 Mar; 26(6):265-8. PubMed ID: 9122123
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and management of methotrexate-induced neurotoxicity in pediatric patients with osteosarcoma: a single-center experience.
Peled Y; Levin D; Shiran S; Manisterski M; Shukrun R; Elhasid R
Int J Clin Oncol; 2022 Aug; 27(8):1372-1378. PubMed ID: 35639227
[TBL] [Abstract][Full Text] [Related]
16. Unexpected severe hepatic and skin toxicities during high dose methotrexate course for osteosarcoma.
Salaün H; Le Nail LR; Simon C; Narciso B; De Pinieux G; Vegas H; Vinceneux A
J Oncol Pharm Pract; 2022 Sep; 28(6):1458-1464. PubMed ID: 35138194
[TBL] [Abstract][Full Text] [Related]
17. Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure.
Nemoto T; Imai C; Kaneko U; Takachi T; Iwabuchi H; Tanaka A; Nakamura G; Ogose A; Uchiyama M
Pediatr Hematol Oncol; 2009; 26(7):520-5. PubMed ID: 19863208
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
19. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
20. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
